Natsimbio National Immunobiology Company

The National Immunobiological Company, part of the Rostec State Corporation, was established in 2013 as a management organization to form a holding company in the field of development and production of immunobiological products. The purpose of the holding is to ensure the independence of Russia from the import of drugs, especially immunobiological drugs and drugs for the treatment of infectious diseases, through the development of its own production and scientific competencies.

Aktivs

The holding as of August 2016 includes:

• NPO "Microgen,"
• "FORT,"
• "Synthesis,"
• MPO "Metalist."

• 37% in the joint venture "Kirov Plasma" (since March 2017).

Directions of development

The company's development is carried out in five main segments of the pharmaceutical market:

• vaccines of the National Calendar of Preventive Vaccinations (NCPP);
• antituberculosis drugs;
• blood preparations;
• drugs for the treatment of HIV and hepatitis;
• insulins and analogues thereof.

The holding's development strategy in 2016, in particular, provides for the production by 2020 of up to 100% of the national need for vaccines under the NCPP and blood plasma factors in physical terms, up to 80% of anti-tuberculosis drugs and 20% of drugs against HIV and hepatitis B and C at the holding's facilities.

It was announced that in the future Natsimbio will unite production enterprises, research and development centers. In cooperation with Russian and foreign companies, the holding will carry out the production of the most important drugs, the development of innovative drugs, the construction and equipment of created and modernized enterprises.

It is planned to establish a number of joint ventures with partners in order to ensure the transfer of technologies and the organization of the production of drugs in full-cycle conditions, including pharmaceutical substances, in the Russian Federation.

The total investment in the development of production within the framework of the strategy by 2020 should amount to 25 billion rubles. The planned total annual revenue of the holding in 2020 is about 40 billion rubles.

Performance indicators

2015: 20-fold increase in net income, double revenue

The net profit of the Rostec division - the National Immunobiological Company (Natsimbio) - increased in 2015 almost 20 times, to 648.5 million rubles, and revenue - twice, the Vedomosti newspaper writes with reference to its report on RAS^[1].

More than half of the revenue - about 484 million rubles. - brought financial bonuses from suppliers. The reason for the growth in profits was the same premiums, as well as fines paid by suppliers, and income from the placement of free funds.

or not to pay a premium is up to the supplier," a Natsimbio spokeswoman said. According to her, payment is possible when purchasing a large batch of goods, early payment, etc. The Natsimbio report reflects bonuses under contracts executed not only in 2015, but also in 2014. It follows from the report that such premiums do not change the cost of goods and the price of the contract and are not subject to VAT.

Premiums were paid by four suppliers - Rosta (11 million rubles), Pharmstor Company (375.3 million rubles), MBA-Group (93.5 million rubles) and Farmasintez (4 million rubles).

It is assumed that in this way drug suppliers give Natsimbio a discount.

"Since they do not want to sell drugs at a price below the maximum price established by the state, they issue supplies for Natsimbio at the maximum price, and then return part of the cost in the form of premiums," the source of the publication from the pharmacological region believes.

An employee of another pharmaceutical manufacturer supplying drugs for public procurement does not exclude that Natsimbio suppliers are forced to underestimate prices in the markets where this company is a monopolist.

Earlier it was reported that the pharmaceutical subsidiary of Rostec wants to absorb the insulin market.

History

2021

Appointment of Andrei Zagorski as General Director

In November 2023, the pharmaceutical holding Natsimbio"," part of the state corporation Rostec"," announced the appointment of Andrei Zagorski as the new general director. Previously, he led the company as acting general director. here More.

Natsimbio became the 100% owner of NPO Microgen

On September 8, 2021, it was announced that Natsimbio became the 100% owner of NPO Microgen. Previously, this scientific and production organization belonged to the Federal Property Management Agency. Read more here.

Procurement of vaccines against coronavirus for 58.5 billion rubles

In July 2021, Natsimbio purchased vaccines against the coronavirus COVID-19 for a total of 58.5 billion rubles. This is evidenced by the data of the unified information system in the field of procurement.

In total, six contracts were concluded, under which the drugs must be delivered by the end of 2021. All vaccines will be delivered at the maximum price. In total, suppliers pledged to supply 67.8 million doses.

In two contracts, we are talking about the supply of 57 million doses of vaccine at a cost of one package of 953.49 rubles. The latter indicator corresponds to the maximum price of the Sputnik V vaccine, including VAT, but the names of the drugs do not appear in the purchases. Of the declared volume, 56.4 million doses should be shipped by October 31, 2021, the rest - by December 31.

Natsimbio buys coronavirus vaccines worth 58.5 billion rubles

Also, the supplier by the end of 2021 will have to supply 10 million doses of vaccine for 3.77 billion rubles. Based on the cost of packaging, we are talking about Sputnik Light (the maximum registered price with VAT and the purchase price is 376.6 rubles).

In addition, Natsimbio will receive 761.8 thousand doses of vaccine by the end of 2021, the cost of which (466.1 rubles per dose) coincides with the maximum price of EpiVacCorona from the State Research Center of Virology and Biotechnology "Vector" by 352.8 million rubles and 20.3 thousand doses of "KoviVaka" from the Center named after M.P. Chumakov for 9.7 million rubles (based on the cost of the dose of 476.3 rubles).

On July 21, 2021, the Moscow Department of Health announced that the EpiVacCorona coronavirus vaccine in the city is enough only for those who have already made the first vaccination, and now makes the second injection. It is not yet available to everyone.

The next batch of vaccine was sent to the regions the day before. We are talking about 40.4 thousand doses. Deliveries to the regions are carried out by the Natsimbio holding from the Rostec state corporation. At the moment, more than 3.1 million doses of this vaccine have been introduced into civilian circulation.^[2]

Sale of a stake in the pharmaceutical company Sintez

At the end of March 2021, Rostec announced the sale of its stake in Synthesis. We are talking about 32.4% of the authorized capital of the pharmaceutical company, which was acquired by AFK Sistema through its subsidiary Sistema Telecom Assets. As part of the transaction, the seller was Natsimbio, a member of Rostec. The financial component of the agreement has not been disclosed. Read more here.

Natsimbio is a single supplier of the Sputnik V vaccine in Russia

In March 2021, the National Immunobiological Company (Natsimbio, part of Rostec) became the single supplier of the Sputnik V coronavirus vaccine COVID-19 in Russia. Earlier, the logistics for the supply of the drug was carried out by the Immunotechnologies company (part of the Sber group).

The fact that Natsimbio became the supplier of Sputnik V was reported by Vedomosti, citing a source close to Immunotechnologies. The Ministry of Health of the Russian Federation confirmed this information and noted that this company has extensive experience in the supply of vaccines within the framework of the national vaccination calendar.

Natsimbio is a single supplier of the Sputnik V vaccine in the Russian Federation

According to GxP news, the government's order to transfer powers to Natsimbio was signed on March 15. Three sources familiar with the situation told the publication about this. The interlocutors indicated that in the fourth quarter of 2020, the government issued an order appointing Immunotechnologies as the vaccine supplier.

RNC Pharma Development Director Nikolai Bespalov, in a conversation with Vedomosti, said that he does not exclude the connection between the transfer of powers to Natsimbio and the fact that the mass release of the vaccine is finally ensured, and this company has more competencies in the supply of a significant amount of such drugs nationwide.

At the end of February 2021, the maximum selling price for Sputnik V was halved - from 1942 to 866 rubles, recalls DSM Group CEO Sergei Shulyak. Because of this, according to him, it became unprofitable for Immunotechnologies to deal with the logistics of the vaccine, and the company itself was not against transferring the relevant powers. Shulyak also suggests that when the government initially faced the choice of who to appoint as the sole supplier, Natsimbio itself was not ready to take on this role.

Natsimbio supplies vaccines for the National Calendar of Preventive Vaccinations, which may include a vaccine against COVID-19.^[3]

2020

Natsimbio is the sole owner of Fort

At the end of December 2020, it became known about the increase in the share of the Natsimbio holding (part of the state corporation Rostec"") in the biopharmaceutical company Fort"" - from 25% to 100%. here More.

Natsimbio was appointed the only vaccine supplier until 2021

The Cabinet of Ministers of the Russian Federation chose Natsimbio as the only vaccine supplier for 2020-2021. This was announced in mid-May 2020 by Rostec, which includes National Immunobiological Company JSC.

Determine JSC "National Immunobiological Company" as the sole executor of purchases of immunobiological drugs carried out by the Ministry of Health of Russia in 2020-2021, the production of which is carried out at all stages of the technological process in the Russian Federation, in order to carry out preventive vaccinations included in the national calendar, - said in the order signed by the Acting Prime Minister of the Russian Federation Andrei Belousov.

Natsimbio will continue to supply vaccines of the National Calendar of preventive vaccinations in 2020-2021

In particular, the holding will supply vaccines for the prevention of influenza, diphtheria, tetanus, hepatitis B, tuberculosis, measles, etc., the document says.

The order also provides the opportunity for Natsimbio to attract subcontractors and co-executors, but only if the holding itself fulfills at least 10% of the total value of obligations under state contracts. At the same time, the Ministry of Health of the Russian Federation was instructed to monitor prices for purchased immunobiological drugs.

In recent years, we have confirmed the effectiveness and feasibility of the work of the main supplier of vaccines used for all-Russian routine vaccination on the market, "says Andrei Zagorski, General Director of Natsimbio, commenting on the appointment of the company as the only supplier of immunobiological drugs to the Ministry of Health. - We introduced the practice of priority supplies, created an effective logistics system, expanded production to timely provide vaccines to a wide network of counterparties throughout the country.[4]

2018

Natsimbio Board of Directors approved

The National Immunobiological Company, in connection with the development of cooperation and the merger of pharmaceutical assets of the state corporation Rostec and Marathon Group, as well as a change in the joint-stock structure of Natsimbio itself, updated the composition of the Board of Directors in February 2018.

Thus, the Natsimbio Council for the first time included three representatives of the Marathon Group:

• Marathon Group President Alexander Vinokurov,
• Chairman of the Board of Marathon Group Sergey Zakharov,
• Elena Milinova, Director of Economics and Finance of Marathon Group.

In turn, the following members of the previous composition retained their seats on the Council:

• Deputy General Director of Rostec State Corporation, Alexander Nazarov who was also elected Chairman of the Board of Directors,
• Deputy Minister of Health of the Russian Federation Tatyana Yakovleva,
• General Director of Natsimbio Andrei Zagorski,
• Head of Financial Planning and Social Programs of the Department of Economics and Finance of Rostec State Corporation Yulia Tsvetkova.

The council was left by the president of the Vi Holding group of companies, advisor to the general director of Rostec Vitaly Maschitsky, executive director of Rostec Oleg Yevtushenko and head of the legal work department of the legal support and corporate governance function of the state corporation Zhanna Skorina.^[5]

Rostec received 79% of Natsimbio while the latter will be a monopoly drug supplier

On February 12, 2018, in Moscow, the General Director of Rostec State Corporation Sergey Chemezov and the President of Marathon Group Alexander Vinokurov signed a Joint Stock Agreement with respect to the joint-stock company National Immunobiological Company (Natsimbio). Earlier, on December 19, 2017, the transaction was approved by the Supervisory Board of Rostec State Corporation.

In accordance with the signed Shareholder Agreement, the Natsimbio shareholder structure is formed as follows: 75% minus one share of the authorized capital belongs to Rostec, 25% plus one share - Marathon Group. Rostec, represented by Natsimbio, receives a 49% stake in SIA Group, owned by Marathon Group, while it provides for the possibility of a significant increase in this share in the future. In turn, Marathon Group receives an option to acquire up to 100% of Natsimbio shares in the event that Natsimbio loses the status of the only supplier of medicines and medical devices in accordance with the order of the authorized state body of the Russian Federation.

The perimeter of the transaction includes shares/stakes owned by the parties in the factories Sintez, Fort, Kirov Plasma, Farm Aid Ltd, NICK Logistics and SIA Group.

Agreements on the merger of pharmaceutical assets of Rostec State Corporation and Marathon Group on the basis of Natsimbio to create a federal-scale manufacturer and supplier of pharmaceutical products were reached in August 2017. The project is an example of a public-private partnership and is aimed at attracting additional competencies and investments for the development of key areas of domestic pharmacology.

2017: Signing an agreement with Kedrion to establish Kirov Plasma JV

The National Immunobiological Company, Pharmstandard and Kedrion Biopharma (Italy) signed an agreement on the creation of Kirov Plasma joint-stock company in March 2017. The company will develop and implement a program for the production of medicinal products obtained from human blood plasma in the Russian Federation on the basis of the Kirov plant. The share of Kedrion Biopharma in the authorized capital is 25%, Natsimbio and Pharmstandard - 37.5% for each company. For more details, see "Kirov Plasma."

' 'Подписание проходило в здании Ростеха в присутствии генерального директора Госкорпорации Sergey Chemezov Acting Governor of the Kirov Region Igor Vasiliev. "

2016

Maryam Khubieva replaced Nikolai Semenov as CEO

On August 11, 2016, it was announced that Maryam Khubieva, who previously worked for Roszdravnadzor and large pharmaceutical companies, became the new CEO of Natsimbio.

Rostec sets the National Immunobiological Company the task by 2020 to increase revenue to 40 billion rubles. Achieving such an indicator is possible if a number of new joint projects are launched with market participants on the transfer of technologies for the production of drugs and medical devices.

In order to maximize the development of the Bio cluster, the management of the State Corporation decided to concentrate the activities of Nikolai Semenov, who previously held the position of General Director of Natsimbio, on the development of the production of Russian medicines and medical devices, as well as the search for new investment projects.

"For two years, Natsimbio's revenue has grown to 7.1 billion rubles. The net profit of the holding in 2015 amounted to 648 million rubles, which is 20 times higher than the same indicator for 2014. During these 2 years, the holding has become a full-fledged player in the pharmaceutical industry. However, now our main task is to build interaction and increase partnerships with all market participants, "said Sergey Chemezov, General Director of Rostec State Corporation

The expansion of the portfolio of joint projects "Natsimbio" as the general director of the holding should be Maryam Khubieva.

"Rostec has set a very ambitious task for the holding - within four years Natsimbio should increase revenue by more than 5 times. Such indicators can only be achieved by building an effective and mutually beneficial partnership with other market participants with the general task of promoting Russia's independence in the field of drug production. The development and launch of new joint projects is our main task for the near future, "said Maryam Khubieva, taking over as general director of Natsimbio.

Plan for the creation of a joint venture with the Italian Kedrion for the production of plasma drugs

On June 17, 2016, it became known that the National Immunobiological Company (Natsimbio), which is part of Rostec, agreed with the Italian company Kedrion to create a joint venture (JV) and buy a share from Belarusian Farmland in the Minsk enterprise for the production of human plasma preparations. We are talking about total investments of 5.5 billion rubles.

As follows from the message of Rostec, the joint venture Natsimbio and Kedrion is formed on the basis of the Rosplazma complex in Kirov. The partners will complete the construction of this plasma production plant. Production will be launched in 2019 and will allow the processing of 600 tons of plasma annually. Investments in the project are estimated at 4 billion rubles.

Natsimbio invests 5.5 billion rubles in the production of blood plasma preparations

"The plant in Kirov is of strategic importance for our holding and in general for Russian healthcare, which is constantly dependent on foreign suppliers of drugs for patients with hemophilia, immunodeficiency diseases, cancer patients," says Nikolai Semenov, head of Natsimbio. - It is extremely important for us that our partner - Kedrion - is one of the largest plasma processors in the world and in total can process up to 2.5 million liters of plasma annually. In addition, it is extremely important for us that our Italian partners not only provide technology, but also invest money in the construction of the Kirov plant. "

After the launch of the enterprise in Kirov, the current need for domestic health care in albumin, immunoglobulin and, to a large extent, in blood clotting factors will be fully met.

As for the plant in, in Minsk 2018 it is planned to start industrial production of medicines there. At this stage, production will fully cover the needs of citizens Belarus for blood preparations (subsequently, the needs). Russia 1.7 billion rubles will be invested in this project.

Launch of a program for the production of drugs for the treatment of HIV infection and viral hepatitis

Within the framework of the PMEF-2016, the National Immunobiological Company of Rostec State Corporation signed an agreement with the Indian company Cipla on the transfer of technologies for the production of pharmaceutical substances, as well as the production of finished dosage forms of combined drugs for the treatment of HIV infection and viral hepatitis. In addition, an agreement was signed with the Russian company ChemRar on the joint development and production of innovative ARV drugs. The range of drugs planned for release fully complies with treatment regimens, as well as WHO recommendations for the organization of ARV therapy.

The agreement with the world's leading company for the production of ARV drugs, Cipla, providing for the transfer of technologies for drugs for the treatment of HIV and viral hepatitis, was signed by Natsimbio CEO Nikolai Semenov and Head of Corporate Strategy and Evaluation of New Projects of the pharmaceutical company Cipla Chawla Chandru Jaswant.

2015: Unified supplier of domestic immunobiological drugs for the Ministry of Health

On June 17, 2015, by order of the Government of the Russian Federation, the National Immunobiological Company for the period 2015-2017 was determined to be the only supplier of domestic immunobiological drugs, the purchase of which is carried out by the Ministry of Health of Russia in order to carry out preventive vaccinations included in the national calendar of preventive vaccinations (NCPP).

2014

Revenue for the year 3.1 billion rubles

The main results of the National Immunobiological Company in 2014: revenue - 3.1 billion rubles; net profit - 0.03 billion rubles.

The only supplier of a number of drugs for the Federal Penitentiary Service of Russia

By order of the Government of the Russian Federation of July 2, 2014 No. 1193-r, JSC "National Immunobiological Company" was determined to be the only supplier of a number of drugs and medical devices, the purchase of which is carried out by the Federal Penitentiary Service of Russia in 2014-2016.

2013: Creation of a company within the framework of Rostec Holding

The National Immunobiological Company was established as part of the state corporation Rostec on October 29, 2013 as a management organization for the formation of a holding company in the field of development and production of immunobiological products.

Notes